Cellectis SA (NASDAQ:CLLS) – Stock analysts at Jefferies Financial Group cut their FY2021 earnings per share estimates for Cellectis in a research report issued to clients and investors on Wednesday, May 8th. Jefferies Financial Group analyst B. Amin now anticipates that the biotechnology company will post earnings per share of $1.13 for the year, down from their previous estimate of $1.20. Jefferies Financial Group also issued estimates for Cellectis’ FY2022 earnings at $2.10 EPS.
Other analysts also recently issued reports about the stock. BidaskClub downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a report on Tuesday, March 26th. ValuEngine raised shares of Cellectis from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Citigroup reduced their price target on shares of Cellectis from $37.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, March 11th. Barclays reissued a “buy” rating and issued a $50.00 price target on shares of Cellectis in a report on Wednesday, March 13th. Finally, William Blair assumed coverage on shares of Cellectis in a report on Wednesday, March 13th. They issued an “outperform” rating for the company. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $32.00.
Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.14. Cellectis had a negative net margin of 401.24% and a negative return on equity of 14.85%. The firm had revenue of $3.08 million during the quarter, compared to the consensus estimate of $7.46 million.
Several large investors have recently added to or reduced their stakes in CLLS. Financial Gravity Companies Inc. bought a new position in shares of Cellectis during the 4th quarter worth about $71,000. Financial Gravity Wealth Inc. bought a new position in shares of Cellectis during the 1st quarter worth about $96,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Cellectis by 37.6% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,545 shares of the biotechnology company’s stock worth $109,000 after acquiring an additional 1,787 shares during the period. Two Sigma Investments LP bought a new position in shares of Cellectis during the 4th quarter worth about $180,000. Finally, KBC Group NV lifted its holdings in shares of Cellectis by 22.9% during the 4th quarter. KBC Group NV now owns 14,266 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 2,661 shares during the period. 29.58% of the stock is owned by institutional investors.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Featured Article: Analyzing a company’s cash flow statement
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.